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Background: Childhood Apraxia of Speech is an impairment of speech motor planning that manifests as difficulty
producing the sounds (articulation) and melody (prosody) of speech. These difficulties may persist through life and
are detrimental to academic, social, and vocational development. A number of published single subject and case
series studies of speech treatments are available. There are currently no randomised control trials or other well
designed group trials available to guide clinical practice.
Methods/Design: A parallel group, fixed size randomised control trial will be conducted in Sydney, Australia to
determine the efficacy of two treatments for Childhood Apraxia of Speech: 1) Rapid Syllable Transition Treatment
and the 2) Nuffield Dyspraxia Programme – Third edition. Eligible children will be English speaking, aged 4–12 years
with a diagnosis of suspected CAS, normal or adjusted hearing and vision, and no comprehension difficulties or
other developmental diagnoses. At least 20 children will be randomised to receive one of the two treatments in
parallel. Treatments will be delivered by trained and supervised speech pathology clinicians using operationalised
manuals. Treatment will be administered in 1-hour sessions, 4 times per week for 3 weeks. The primary outcomes
are speech sound and prosodic accuracy on a customised 292 item probe and the Diagnostic Evaluation of
Articulation and Phonology inconsistency subtest administered prior to treatment and 1 week, 1 month and
4 months post-treatment. All post assessments will be completed by blinded assessors. Our hypotheses are: 1)
treatment effects at 1 week post will be similar for both treatments, 2) maintenance of treatment effects at 1 and
4 months post will be greater for Rapid Syllable Transition Treatment than Nuffield Dyspraxia Programme treatment,
and 3) generalisation of treatment effects to untrained related speech behaviours will be greater for Rapid Syllable
Transition Treatment than Nuffield Dyspraxia Programme treatment. This protocol was approved by the Human
Research Ethics Committee, University of Sydney (#12924).
Discussion: This will be the first randomised control trial to test treatment for CAS. It will be valuable for clinical
decision-making and providing evidence-based services for children with CAS.
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To date the consensus in the literature is that Childhood
Apraxia of Speech (CAS) is a disorder of speech motor
programming and planning with genetic, neurologic, or
idiopathic causes [1-4]. Children with the disorder have
significant speech impairments due to an inability to
control placement and timing of lip, tongue and vocal
movements. These impairments result in inconsistent
productions of the same words, difficulty sequencing
speech sounds together to form fluent words and sen-
tences and impairments of the melody (i.e. prosody) of
speech. The speech of these children is often unintelli-
gible and the disability can persist throughout the life-
span, despite normal intelligence and comprehension of
language [5,6]. The impaired development of speech has
flow on effects, frequently disrupting development of
reading, spelling and writing skills (e.g. learning letter-
sound relationships for deciphering new words), social
communication, and academic potential [6,7]. Adults
with speech disorders (including persistent CAS) are
known to have a lower socio-economic status than non-
speech disordered peers, an increased incidence of de-
pression and may select occupations that require little or
no personal interaction despite normal intelligence
[6,8,9]. Speech pathologists frequently report that chil-
dren with CAS make slow progress in treatment and
show deterioration or loss of skills once treatment stops
[10,11]. It is unclear if this is due to the child’s impaired
motor learning or to a lack of evidence to inform effect-
ive treatment [10,12,13]. Due to CAS’s characteristics
and associated risk factors, the ultimate aim of treatment
must be long term maintenance of learned skills and
generalisation of treatment effects to improvement
across untrained but related speech skills and speaking
contexts.
There are few rigorous treatment studies published for
CAS currently and no randomised control trials to date
[1,14]. The best evidence available consists of single case
experimental designs and case series for a range of dif-
ferent treatments across different age ranges with sam-
ples sizes no greater than twelve (e.g. [15]). Published
speech-focussed treatments with some replicated evi-
dence include the Rapid Syllable Transition Treatment
(ReST) [12,16], Dynamic Temporal and Tactile Cueing
(DTTC) [17,18] and the Nuffield Dyspraxia Programme
- Third edition (NDP3) [19-21]. Replicated evidence also
exists for pre-reading and spelling interventions
[15,22,23] and alternative or augmentative communica-
tion methods [24-28] that work on communication
skills. These methods are the best poised to be utilised
clinically at present and also to be included in any con-
trolled trial. Other published evidence includes studies
on melodic-intonation therapy (speech melody) therapy
[29] and speech rate control [30]. Recently, interventionstudies have included combined approaches such as a
combined stimulability and core vocabulary approach
[31] and a combined melodic intonation therapy and
touch-cue method [32]; the PROMPT approach [33] and
technological interventions providing graphic displays of
tongue movements during speech such as electropalato-
graphy [20,34]. Moreover there are many published
commercial programmes for CAS, which have no pub-
lished evidence to date. Examples include the Kaufman
Speech Praxis Treatment Kits [35-37] and the Easy Does
It For Apraxia series [38,39]. It is relevant to note that
children with CAS have different needs as their skills
change with maturation and therapy and so it is plaus-
ible that multiple treatments will be effective but for dif-
ferent symptoms, severities and ages. In summary, while
consumers and clinicians have a range of potential inter-
vention programmes available, few have been experi-
mentally tested and none have been experimentally
compared. A Cochrane review on the topic states “there
is a critical lack of well controlled treatment studies
addressing treatment efficacy for CAS” [14] pg 2.
Nuffield Dyspraxia Programme – Third edition (NDP3)
At time of writing, the Nuffield Dyspraxia Programme is
in its third edition and has been utilised in clinical prac-
tices in Australia and the United Kingdom for approxi-
mately 30 years [40,41]. The comprehensive treatment
package includes its own assessment as well as a list of
over 500 words to be targeted in therapy, and corre-
sponding therapy stimulus pictures. The theoretical basis
of the programme is that motor learning is complex and
hierarchical; one needs to perform frequent and system-
atic practice to master foundation levels before progres-
sing to harder, more complex speech patterns. Here
mastery is defined as fluent, automatic and independent
production of targeted speech behaviours. To date, a
total of five empirical case studies have demonstrated
positive outcomes for this treatment alone [19,21], or in
conjunction with electropalatography therapy [20].
Given these results and the programme’s broad dissem-
ination, testing the programme in a randomised control
trial is appropriate.
Rapid Syllable Transition Treatment (ReST)
The ReST treatment is a more recently conceived and
tested treatment approach [12]. The programme is
grounded in theory of motor control and learning and is
informed by an extensive motor learning literature [42].
The ReST treatment applies Principles of Motor Learn-
ing [43] with an aim to maximise long-term mainten-
ance and generalisation of treated speech skills in
children with CAS. ReST involves intensive practice in
producing multisyllabic pseudo-words (e.g. toobiger) to
improve the accuracy of speech sounds, the ability to
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to the next, and control of the melody in the form of
relative emphasis, or stress, placed on each syllable
within a word. Pseudo-words are used to mimic novel
word learning and this allows children to develop and
practice new speech patterns without interference from
existing erroneous speech patterns. There is published
evidence that the effects of speech treatment using pho-
notactically permissible pseudo-words (non-words) gen-
eralise to improved production of real words of similar
or easier composition and complexity [44]. ReST
involves two components within each treatment session.
The first is a Pre-Practice (or training) Component
where the stimuli are taught with cues to shape accurate
production and immediate, specific feedback is given
after each production. This is followed by a longer Prac-
tice Component incorporating those Principles of Motor
Learning that have been shown to facilitate long-term
learning and generalisation of skill. For example, “right/
wrong” (i.e. Knowledge of Results or KR) feedback is
provided by the clinician, fading from high frequency to
low frequency over the session (i.e. provided on a total
50% of responses) and this KR feedback is delayed with
a silent interval between response and feedback to en-
courage self-evaluation. Two published case series in-
volving a total of ten children [12,16] indicate strong
clinical effects for ReST treatment, motivating further
study in a phase three trial.
Based on these foundational studies, we are well
poised to conduct a larger scale clinical trial of ReST
treatment against NDP3. Our hypotheses for this
planned randomised control trial are: 1) treatment gains
from pre-treatment to 1 week post-treatment will be
similar for both treatments, 2) ReST treatment will re-
sult in greater maintenance of treatment effects at 1 and
4 months post-treatment than NDP3 treatment, and 3)
ReST treatment will result in greater generalisation of
treatment effects to untrained but related speech beha-
viours at 1 week, 1 month and 4 months post-treatment
than NDP3 treatment.
Methods and design
A parallel group, fixed size randomised control trial will
be conducted in Sydney, Australia to determine the
comparative efficacy of two treatments for Childhood
Apraxia of Speech: the Rapid Syllable Transition Treat-
ment (ReST) and the Nuffield Dyspraxia Programme –
Third edition (NDP3). This protocol has been approved
by the Human Research Ethics Committee of the Uni-
versity of Sydney (approval number 12924).
A power calculation has been used to determine the
number of participants to be recruited. Previous pre and
post treatment data from within-subject ReST studies (e.g.
[12,16]) for a total number of 14 participants demonstratedstatistically significant differences for 12 of the 14 partici-
pants and large effect sizes (Cohen’s d=1.36). Based on this,
the estimated sample size to detect a reliable treatment ef-
fect (alpha level 0.05, beta level 80%) is 6 per group for this
RCT. We have no estimates for the NDP3 due to lack of
published effect sizes or data to enable calculation of an ef-
fect size. On this basis we propose 10 per group to allow
for attrition and to accommodate the higher heterogeneity
with a between-subjects design.
Participants
Participants will be recruited via flyer and email adver-
tisement and all interventions will be undertaken at the
University of Sydney. The participant’s caregivers will be
asked to provide informed consent for a child to partici-
pate prior to admission into the study in accordance to
our ethics approval.
Inclusion criteria will be: a) clinical diagnosis of sus-
pected CAS, b) between 4 and 12 years of age, c) com-
prehension skills within 1 SD of the mean for a child’s
chronological age (based on normative data for the re-
ceptive language score from the Clinical Evaluation of
Language Fundamentals (CELF) - Fourth edition or
CELF Preschool - Second edition [45,46], d) normal or
adjusted-to-normal hearing and vision, e) the child and
at least one parent as native Australian English speakers,




All potential participants will be screened over the
phone and by requesting any speech pathology or other
relevant reports to determine if children are likely to
meet the inclusion criteria. Any overt contraindications
should be determined at this time (e.g. other develop-
mental diagnoses).
Eligibility assessment
All potential participants who are not excluded during
telephone screening will participate in a two-hour as-
sessment to ensure they meet the inclusion criteria and
meet the diagnostic criteria for CAS. The current gold
standard in CAS diagnosis is expert clinical opinion as
there are no validated standardised assessments available
[13]. Accordingly CAS diagnosis will be made by the
first author according to the ASHA (2007) criteria [1] as
well as Strand’s 10 point checklist [47] where each of the
ten items are assessed across three tasks and a diagnosis
of CAS is made if a child scores four or higher on the
checklist. Diagnoses will be verified by the second au-
thor blinded to the first author decision.
The eligibility assessment includes a case history ques-
tionnaire, hearing screening [48], the CELF [45,46] to
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pleting three repetitions within the Inconsistency subtest
of the Diagnostic Evaluation of Articulation and Phon-
ology (DEAP) [49] to determine percentage within-word
consistency across 25 words, the Test of Polysyllables
[50,51] to document phonemic and phonetic level errors
in words with greater complexity, a 100-utterance con-
nected speech sample [52] and an oral structural and
functional examination [53].
Diagnostic assessment
Eligible participants will undergo a further two hours of
assessment to describe their broader communication
skills. The further assessment will test memory and pro-
cessing skills using the Children’s Test of Nonword
Repetition [54], Comprehensive Test of Phonological
Processing [55], Test of Auditory Processing Skills (3rd
edition) [56] (verbal memory, auditory discrimination);
processing and production of prosody using the PEPS-C
Test of Prosody [57]; and severity of articulation dis-
order using the Goldman-Fristoe Test of Articulation -
Second edition (GFTA-2) [58]. Finally, an estimate of
verbal cognitive ability will be obtained with the Peabody
Picture Vocabulary Test – 4 [59,60] .
Baseline assessment probe
One further hour of assessment will be undertaken using
a specially designed probe of 292 single sounds, words
and phrases using a PowerPoint presentation to establish
baseline performance on treated and untreated experi-
mental stimuli. The first 162 stimuli are the Nuffield
Dyspraxia Programme’s Dyspraxia Assessment stimuli
[41] consisting of a variety of single consonants (e.g. ‘s’
or ‘d’), vowels (e.g ‘ah’ or ‘oo’), one syllable words (e.g.
‘no’, ‘up’ and ‘moon’), two syllable words (e.g. ‘dinner’ and
pocket’), multisyllable words (e.g. ‘banana’ and ‘caterpil-
lar’), words with clusters or blends (e.g. ‘star’ or ‘fast’)
and phrases (e.g. ‘do you like jelly?’ and ‘I saw five
camels at the zoo’). In addition, 80 nonsense words will
be probed as stimuli for the ReST program, with 40
designated as treatment stimuli and another 40 as un-
treated stimuli. Each set of 40 words will be individua-
lized based on the child’s speech skills and stimulus
selection criteria for the ReST programme. Twenty will
be at the child’s current level (e.g. two syllable CVCV
words e.g. ‘tegar’) and the other twenty will be the
related next step (e.g. ‘tegarfer’) to allow for assessment
of treatment gains if progression criteria are met in the
intervention period. The final component of the probe
will be 50 untreated words of one, two and three sylla-
bles to measure potential generalisation of treatment
effects to untreated speech behaviours for both treat-
ments. All real words will be pictured and written on
screen. All ReST stimuli will be written on screen.Participants with adequate reading skills will read the
pseudo-word stimuli, those who cannot read will be
asked to imitate a model. A pre-recorded model of all
stimuli said by one Australian English speaker will be
available to ensure consistency in delivery across exami-
ners if imitation is required. The PowerPoint presenta-
tion will also include built in standardised breaks and
animations to promote interest and motivation for the
participants. Each participant will have individualised
stimuli chosen for them for both programmes based on
their assessment performance prior to randomisation,
group allocation and treatment.Group allocation
Participants will be consecutively allocated a participant
number from 1–30. Participants will be randomised to
treatment condition utilising concealed allocation. That
is, cards with treatment name (ReST or NDP3) will be
placed in opaque envelopes, an independent person will
then randomly draw envelopes and consecutively place
participant numbers 1 to 30 on the front of the envel-
opes without opening them. In this way, each eligible
participant will be randomly allocated to treatment
according to their assigned participant number.Intervention delivery and dosage
The two treatments will be conducted in parallel within
three treatment blocks over school holiday time in Syd-
ney, Australia, permitting a maximum of 10 participants
per block to allow for recruitment of between 20 and 30
participants across 3 treatment blocks. Treatments will
be delivered by trained and supervised speech pathology
clinicians. Each child will be allocated one clinician for
all treatment sessions. Clinicians will be blinded to hy-
potheses. The parents of children will not be informed
of the name and strategies of the treatment their chil-
dren are receiving until after data collection is com-
pleted to ensure no home practice will be attempted.
All participants, regardless of treatment condition, will
receive the same amount of time in treatment with 1-
hour sessions, four times a week for three weeks for a
total of 12 treatment hours. All participants will
complete between 100–120 production trials on treat-
ment words per 1-hour session (i.e. a total of 1200 to
1440 responses during treatment), to match the practice
intensity and session distribution of our pilot studies of
ReST [12,16] and the current best evidence of treatment
intensity for CAS [61]. For the NDP3 programme this
will equate to approximately 30–40 trials during each 18
minute period for each goal. For the ReST programme,
this will equate to 5–20 Pre-Practice trials and 100 prac-
tice trials.
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We have operationalised the NDP3 programme with the
assistance of its original authors to ensure dosage and
other aspects will be controlled with the other treatment
and yet we will be faithful to the original programme.
Therapy will be conducted in accordance with the tenet
of the NDP3 and the operationalised manual which was
developed for this study, and treatment fidelity will be
evaluated to ensure compliance.
Treatment goals and stimuli In the NDP3, treatment
goals are selected through assessment of a child’s speech
sound, melody (prosody), vocal and nasal quality
strengths and needs. Three independent goals will be
selected according to the NDP3 hierarchy ‘Treatment
Planning and Progression’ checklist in the original man-
ual [41] with the intention of building on their strengths
to facilitate learning of a new speech pattern or incorp-
orate an old pattern or sound into a new more complex
context (e.g. a two rather than one syllable word). Each
of the three individualised goals will involve the child
naming five different pictured stimuli independently
with 90% accuracy. Cues are provided as needed but
only independent productions over at least 12 opportun-
ities are counted towards achieving the goal.
Five sounds or real word stimuli will be chosen per
goal (for example if the goal is ‘single consonant sounds’,
initially selected stimuli will include sounds the child
can produce at least 10%–60% of the time with cues but
would benefit from therapy (e.g. ‘s’, ‘h’ ,‘f ’, ‘m’ and ‘y’). The
original NDP3 pictured stimuli will be used in sessions
[41]. Non-speech (oral-motor) goals will be excluded
from this study to ensure consistent dosage of speech
production intervention across treatments within each
treatment session.
Treatment procedure Each of the three goals will be
worked on in a block of 18 minutes during every session
using game activities. Each treatment task will incorpor-
ate verbal instructions, modelling, articulation, visual-
tactile cues to guide tongue/lip placement (e.g. cued ar-
ticulation [62]) and pictured stimuli to guide children in
modifying their production to say the sound or selected
stimuli accurately. Immediate feedback describing the
child’s performance (e.g. ‘You made a great ‘s’ sound
with your teeth together!’) will be given after every pro-
duction attempt (i.e. on 100% of responses). When a
production is accurate, the child will be asked to repeat
the stimulus item stimuli three times to help consolidate
new motor plans. The child will need to say each stimu-
lus item with 90% accuracy out of at least 12 trials with-
out modelling or cueing from the clinician before it is
removed from treatment and a new target word is intro-
duced. Production accuracy for the acquired word(s) willbe probed at the start of each goal every second session
to ensure maintenance of skill. If performance deterio-
rates, it will be re-introduced into the set of treatment
words and the newest item removed to maintain the
same number of treatment words at all times. Once 5
stimulus items are acquired for a given goal, treatment
will move up the hierarchy to the next level (e.g. once a
consonant-vowel (CV) syllable is achieved, consonant-
vowel-consonant-vowel (CVCV) sequences using the
same speech sounds will be targeted).
Data collection Accuracy of productions will be scored
in every session to track percent accuracy for each
stimulus item and the number of production attempts
requiring clinician cues. These measures will be used to
track treatment gains and in determining if and when to
change treatment targets and/or levels according to the
operationalised NDP3 instructions for this study.
Rapid Syllable Transition Treatment (ReST)
The ReST treatment was initially manualised by the sec-
ond and third author from a verbal description of ReST
treatment by its developer Professor Donald A. Robin, and
with assistance from Jeannie McDonald. The first author
adapted the stimuli and further operationalised the treat-
ment to ensure experimental control in the context of this
parallel RCT. The adapted manual will be used.
Treatment goals and stimuli Treatment for all children
will involve correctly producing selected pseudo-word
stimuli. Each treatment session has two components,
each with a different goal. In the Pre-Practice compo-
nent, the goal is to elicit a total of five correct produc-
tions of any of the pseudo-word stimuli from the
participant. Once this is achieved, treatment moves to
the Practice component, where the goal is for the par-
ticipant to produce the 20 pseudo-word stimuli 5 times
each (n = 100), in random order, with 80% accuracy.
The pseudo-word stimuli for the programme are designed
to be read and conform to phonotactic rules of real English
words [63,64]. Pseudo-words will be either at a two syllable
(CVCV where C = consonant and V = vowel sound) or 3
syllable (CVCVCV) level to target the level immediately
above each participant’s speech skills at assessment. Twenty
child-specific pseudo-words/phrases will be constructed and
used for all 12 treatment sessions: 10 will have a weak-
strong prosodic pattern (e.g. ‘tebor’ or ‘teborfer’) and 10 will
have a strong-weak stress (e.g. ‘farbe’ or ‘farbegee’). The con-
sonant (C) sounds in each word are individualised for each
participant to ensure a) they are sounds they can produce at
least 10% of the time, b) they are maximally different in
terms of place and manner of articulation and voicing to in-
crease variation and complexity and c) are not vowel-like
consonants (e.g. ‘y’ or ‘l’), to facilitate later acoustic analysis.
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and ‘t’, ‘m’ and ‘n.’ Vowel sounds will remain consistent
across participants to ensure the stress patterns remain. No
double-vowels or diphthongs (e.g. ‘eye’ or ‘ay’) will be
included.
Treatment procedure Each session will start with the
Pre-Practice component where the child’s productions of
the pseudo-words are shaped so s/he experiences correct
responses. For the first two sessions, the pseudo-words
will be randomly presented to gain an idea of areas of
difficulty for each participant. From session three to
twelve, difficult pseudo-words that require more shaping
by the clinician will be presented as a primary focus to
ensure correct productions are experienced in Pre-Prac-
tice. Cues will include all, or a subset of, modelling, tap-
ping and breaking words word up into parts and then
putting them together again. Knowledge of performance
(KP) feedback will be given for all trials (e.g. for the
prosodic pattern: “Great soft then strong beat, well
done” or “you said all strong beats.”). The Pre-Practice
component will take most of the session in the first two
sessions, but for the majority of sessions will take ap-
proximately the first 10 minutes. Once any five pseudo-
words are produced correctly, the treatment session will
move into the Practice component.
In the Practice component, the 20 pseudo-words will be
presented orthographically (in written form), in random
order for a maximum of 100 production attempts by the
child. No cues will be provided. Knowledge of results (KR),
or “right/wrong”, feedback will be given after a three sec-
ond delay for 50% of the 100 trials based on a decreasing
feedback schedule (e.g. a randomly selected 9/10 given
feedback for the first ten stimuli down to 1/10 for the final
ten stimuli). After each set of 20 trials, participants will be
given a timed 2 minute break (e.g. to play games or be ac-
tive) to facilitate attention and compliance. Once a child
produces ≥80 of the 100 productions correctly in the Prac-
tice component in two consecutive sessions, therapy pro-
gresses to the next level of difficulty. For children who
started with 2 syllable pseudo-words (e.g. ‘tebor’) they will
move on to the related 3 syllable pseudo-words (e.g. tebor-
fer’). For children who started with 3 syllable words they
will move on to putting the 3 syllable words into carrier
phrases (e.g. ‘Can I have a begarter?’ or ‘It’s his fargeber’).
The Practice component will comprise the majority of each
session (approximately 50 minutes) after sessions 1 and 2.
Data collection In the Pre-Practice component, total
correct productions will be judged perceptually. Each
pseudo-word will be counted for speech sound accuracy
and for production of prosodic pattern (i.e. syllable
stress) and for fluency in sequencing/transitioning of
sounds within the pseudo-word. This will ensure thateach participant is moved to Practice only after produ-
cing five correct responses and allow identification of
areas that need more shaping in Pre-Practice. In Prac-
tice, data sheets will list all 100 pseudo-words in rando-
mised order with asterisks identifying which items are to
receive KR feedback. Space will be provided for the clin-
ician to take data on whether the production of the
whole pseudo-word was judged correct and, if any as-
pect was incorrect, the specific sub-parameter(s) in
error: speech sounds and/or prosody and/or sequencing
control.Treatment fidelity
Treatment fidelity, that is inter-rater reliability for (a) ac-
curacy of response transcription and (b) application of
the manualised protocol in terms of provision of cues,
feedback and repetitions by the clinician, will be calcu-
lated between the clinician and the first author for 10%
of each treatment session. This will document whether
agreement for both measures is ≥85% (the benchmark
for this study). If any variations occur for any treatment
session, the first author will discuss this with the clin-
ician contemporaneously to resolve disagreements in
protocol application for future sessions.Outcome assessment
Outcome assessments and measures
Two hour post-treatment assessments will be scheduled
for 1 week post treatment, 1 month post-treatment (after
the no-treatment period of 4 weeks) and 4 months post-
treatment (after resuming the participant’s usual speech
pathology services for up to 3 months). All assessments
will be completed by blinded independent assessors, that
is no assessor will see the same child twice. Intra-rater
and inter-rater reliability will be calculated for 10% of
every probe completed to ensure transcription and judg-
ments are above 85%. If the benchmark is not met,
assessors will need to re-transcribe the recordings before
discussion on items of disagreement to reach consensus.
The primary outcome will be speech (articulation) and
prosodic (speech melody) accuracy on the specifically
designed 292 item probe [49] administered during base-
line and the three post-treatment assessments. Second-
ary outcome measures will include a) change in percent
inconsistency across three repetitions of twenty-five
words on the DEAP Inconsistency subtest and b) per-
cent phonemes correct on the Test of Polysyllables and
GFTA - 2 administered only at 1 month post-treatment.
The probe and all assessments will be phonetically tran-
scribed using the International Phonetic Alphabet, ex-
cept the DEAP Inconsistency subtest which will use
transcription methods according to the test manual.
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Clinical effect sizes will be reported using Cohen’s d. A
series of repeated measures ANOVA with between subject
factor of treatment (NDP3, ReST) and within subject factor
of time (pre-, 1 week post-, 1 month post-, and 4 months
post-treatment) will be used to determine the relative effi-
cacy of the two treatments as measured by the 292-item
experimental probe. Separate analyses will be run for trea-
ted stimuli, to document treatment and maintenance
effects, and untreated stimuli, to document generalisation
of treatment effects and their maintenance. Additional
repeated measures ANOVA (2 groups x 4 time points) will
be run for the DEAP Inconsistency subtest [49], GFTA-2
[58] and the Test of Polysyllables [50,51]. If there is any at-
trition, an intention-to-treat analysis will be conducted.
Recording and reliability
All assessment and treatment sessions will be audio-
recorded using a Sony ICD-UX71F recorder, and video-
recorded with a Cinde 88 audio-visual-system. The first
two authors will supervise speech pathology clinicians
using the in-house closed circuit video system to observe
sessions from a different room in real-time with minimal
distraction for the children. Professional recorders (Echo
Layla 24/96 multitrack recording system, Marantz
PMD660 solid-state recorder and a Roland Quad-Capture
UA-55) will be used for high-quality audio-recording of
children’s speech for all experimental probes and assess-
ments. Recordings will use 16Bit and 48,000 Hz sampling
rate to allow for future acoustic analysis, if warranted.
Discussion
Potential significance
This will be the first randomised control trial to test any
treatment for CAS [14]. It is predicted that this will be
valuable for clinical decision making and ultimately for
providing evidence-based and timely services for chil-
dren with CAS which may improve access to services
and reduce the burden of the disorder. Potentially both
treatments will be shown efficacious to some degree or
for specific behaviours, which offers two evidence-based
options tested at a gold standard level. If the treatments
are successful, further work in ensuring time-efficient
translation into practice can be pursued in effectiveness
studies, knowing the treatments are efficacious and such
work is warranted. Examples of this may include
computer-based delivery of treatment to promote home
practice and achieve treatment intensity with fewer face-
to-face clinician-directed sessions.
As both treatments also vary in their application of
Principles of Motor Learning, future investigations of
the treatments may explore the effects of these differ-
ences on long-term outcomes. Recently Maas and col-
leagues [13] used DTTC with varied frequency feedbackin treatment – low frequency (feedback on 60% of trials)
and high frequency (feedback on 100% of trials). Two
participants responded more favourably to low fre-
quency feedback yet another responded more favourably
to high frequency feedback, and regardless of feedback
frequency generalisation was limited. Due to a sample
size of three, it is unclear why these patterns may have
occurred. Additionally Maas and colleagues [65]
explored blocked versus random practice in terms of
long-term maintenance and transfer. Again the results
were mixed with two participants favouring blocked
practice, another performing better with random prac-
tice and the fourth participant responding to neither
condition. Our research will not explicitly test these
motor learning principles, as we are using the treatments
as faithfully as possible to their original form. However,
the two treatment approaches differ in their application
of key principles: the NDP3 uses high frequency feed-
back while ReST uses high frequency feedback in Pre-
Practice and low frequency feedback in practice; the
NDP3 uses blocked practice on specific speech targets
but random presentation of words within blocks while
ReST uses random practice in the Practice component.
It will therefore be interesting to analyse the results for
each treatment considering the inherent Principles of
Motor Learning utilised.
Potential limitations
As this is a behavioural treatment, it is not possible to
blind clinicians and participants to treatments as per
CONSORT [66] and PEDro guidelines [67]. Even though
parents will not be told the name or details of the treat-
ment their child will receive until their participation has
ended, they could still talk to another parent in the waiting
room and realise the treatments are different.
Clinicians will conduct all treatment sessions with two
assigned participants using the ReST treatment for one
and the NDP3 treatment for the other. Thus they will be
required to be trained in and deliver both treatments.
This is to reduce potential clinician effects. There is po-
tential for drift across methods, motivating supervision
of sessions by the authors and calculation of treatment
fidelity on a portion of all treatment sessions.
Additional file
Additional file 1: CONSORT Randomised Control Trial Flowchart of
participants through the study [66].
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